^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
intraoperative cisplatin system (PRV211)
i
Other names: PRV211
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Privo Tech
Drug class:
DNA synthesis inhibitor
Related drugs:
1m
Safety and Efficacy Study of PRV111 and PRV211 in Subjects with Oral Squamous Cell Carcinoma (clinicaltrials.gov)
P2/3, N=40, Recruiting, Privo Technologies | Phase classification: P1/2 --> P2/3
Phase classification • Surgery
|
intraoperative cisplatin system (PRV211)
2ms
Safety and Efficacy Study of PRV111 and PRV211 in Subjects with Oral Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=40, Recruiting, Privo Technologies | Trial primary completion date: Jan 2025 --> Aug 2025
Trial primary completion date • Surgery
|
intraoperative cisplatin system (PRV211)
10ms
Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=40, Recruiting, Privo Technologies | Not yet recruiting --> Recruiting
Enrollment open • Surgery
|
intraoperative cisplatin system (PRV211)
over1year
Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=40, Not yet recruiting, Privo Technologies
New P1/2 trial • Surgery
|
cisplatin • intraoperative cisplatin system (PRV211)
Share via
